Director/PDMR Transaction
News Provided by GlobeNewswire2018-06-29
10 Views
Albion Technology & General VCT PLC (the “Company”)
Director/PDMR Transaction
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial / persons closely associated | |||||||
| a) | Name | Patrick Reeve | ||||||
| 2 | Reason for notification | |||||||
| a) | Position/status | PDMR/Director | ||||||
| b) | Initial notification/Amendment | Initial notification | ||||||
| 3 | ) | Details of the issuer, emission allowance market participation, auction platform, | ||||||
| auctioneer or auction monitor | ||||||||
| a) | Name | Albion Technology & General VCT PLC | ||||||
| b) | LEI | 213800TKJUY376H3KN16 | ||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; | |||||||
| (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted | ||||||||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of nominal value 1 penny each | ||||||
| Identification code | GB0005581672 | |||||||
| b) | Nature of the transaction | Issue of Shares under the Dividend Reinvestment Scheme | ||||||
| c) | Price(s) and volume(s) | Price | Volume | Amount | ||||
| £ | 0.727 | 12344 | £ | 8974.09 | ||||
| d) | Aggregated information | |||||||
| - Aggregated volume | 12344 | £ | 8974.09 | |||||
| e) | Date of the transaction | 29 June 18 | ||||||
| f) | Place of the transaction | London Stock Exchange | ||||||
Name of authorised official of issuer responsible for making notification:
Albion Capital Group LLP - Company Secretary
Date of notification
29 June 2018
© 2018 GlobeNewswire, Inc. All Rights Reserved.
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
Bristol Myers Squibb's (NYSE: BMY) Opdivo Plus Yervoy Demonstrates Durable Survival Benefit vs. Chemotherapy in Patients with Previously Untreated Malignant Pleural Mesothelioma
